» Articles » PMID: 38911475

Effects of Aerobic Exercise on Neurocognitive Function in Postmenopausal Women Receiving Endocrine Therapy for Breast Cancer: The Exercise Program in Cancer and Cognition Randomized Controlled Trial

Abstract

Objective: The Exercise Program in Cancer and Cognition (EPICC) Study was a randomized controlled trial (RCT) designed to determine whether six months of moderate-intensity aerobic exercise improves neurocognitive function in women with breast cancer (BC) receiving endocrine therapy (ET).

Methods: Postmenopausal women with hormone receptor+, early-stage BC, within two years post-primary therapy were randomized to the exercise intervention (six months, ≥150 minutes of moderate-intensity aerobic exercise/week) or usual care control condition. Outcomes were assessed at pre-randomization and after intervention completion. Groups were compared using linear mixed-effects modeling.

Results: Participants (N=153) were years old, with stage I BC (64.1%) and a median of 4.7 months post-diagnosis. We found a group-by-time interaction (p=0.041) and a trend for the main effect of time (p=0.11) for processing speed with improved performance in the exercise group and no change in the controls. Similar main effects of time were observed for learning and memory (p=0.024) and working memory (p=0.01). Better intervention adherence was associated with improved processing speed (p=0.017).

Conclusions: Six months of moderate-intensity aerobic exercise improves processing speed in postmenopausal women with BC receiving ET who initiate exercise within two years of completing primary therapy (surgery +/- chemotherapy). This is the first large-scale study to examine the effects of aerobic exercise on neurocognitive function in women with BC. Additional research is needed to address the long-term effects of aerobic exercise on cognitive function.

Citing Articles

Effects of a 6-month aerobic exercise intervention on brain morphology in women with breast cancer receiving aromatase inhibitor therapy: a sub-study of the EPICC trial.

Molina-Hidalgo C, Wan L, Velazquez-Diaz D, Huang H, Grove G, Bender C Front Hum Neurosci. 2024; 18:1443916.

PMID: 39507060 PMC: 11538074. DOI: 10.3389/fnhum.2024.1443916.


Relationship of physical activity and cognitive functioning among breast cancer survivors: a cross-sectional analysis.

Hartman S, Zablocki R, Tam R, Palmer B, Parker B, Sears D Front Cognit. 2024; 3.

PMID: 39483324 PMC: 11526472. DOI: 10.3389/fcogn.2024.1332960.


Role function in postmenopausal women during aromatase inhibitor therapy for breast cancer.

Melnyk H, Dickson V, Bender C, Yu G, Djukic M, Merriman J J Cancer Surviv. 2024; .

PMID: 39425854 DOI: 10.1007/s11764-024-01697-x.


The National Cancer Institute clinical trials planning meeting to address gaps in observational and intervention trials for cancer-related cognitive impairment.

Janelsins M, Van Dyk K, Hartman S, Koll T, Cramer C, Lesser G J Natl Cancer Inst. 2024; 117(2):217-228.

PMID: 39250738 PMC: 11807440. DOI: 10.1093/jnci/djae209.

References
1.
Hartman S, Weiner L, Nelson S, Natarajan L, Patterson R, Palmer B . Mediators of a Physical Activity Intervention on Cognition in Breast Cancer Survivors: Evidence From a Randomized Controlled Trial. JMIR Cancer. 2019; 5(2):e13150. PMC: 6914286. DOI: 10.2196/13150. View

2.
Ren X, Wang X, Sun J, Hui Z, Lei S, Wang C . Effects of physical exercise on cognitive function of breast cancer survivors receiving chemotherapy: A systematic review of randomized controlled trials. Breast. 2022; 63:113-122. PMC: 8976138. DOI: 10.1016/j.breast.2022.03.014. View

3.
Borg G . Psychophysical bases of perceived exertion. Med Sci Sports Exerc. 1982; 14(5):377-81. View

4.
Ahles T, Root J . Cognitive Effects of Cancer and Cancer Treatments. Annu Rev Clin Psychol. 2018; 14:425-451. PMC: 9118140. DOI: 10.1146/annurev-clinpsy-050817-084903. View

5.
Aghjayan S, Bournias T, Kang C, Zhou X, Stillman C, Donofry S . Aerobic exercise improves episodic memory in late adulthood: a systematic review and meta-analysis. Commun Med (Lond). 2022; 2:15. PMC: 9053291. DOI: 10.1038/s43856-022-00079-7. View